Avalo Therapeutics Highlights AVTX-009 Progress in HS

The latest announcement is out from Avalo Therapeutics ( (AVTX) ).

Avalo Therapeutics has released an updated investor presentation in January 2026 detailing progress on AVTX-009, its lead anti-IL-1β monoclonal antibody candidate, which it is positioning as a potential best-in-class and best-in-disease therapy for hidradenitis suppurativa. The company reported that enrollment has been completed in its Phase 2 LOTUS trial in HS, with topline data expected in the second quarter of 2026, and emphasized clinical data suggesting AVTX-009’s high affinity, long half-life and favorable safety profile could enable strong efficacy and less frequent dosing relative to prior IL-1–targeting approaches; combined with a robust leadership team and funding runway into 2028, the update underscores Avalo’s bid to secure a leading role in the rapidly expanding HS treatment market and to extend AVTX-009 into additional immune-mediated inflammatory diseases.

The most recent analyst rating on (AVTX) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.

Spark’s Take on AVTX Stock

According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.

The overall stock score is primarily impacted by significant financial challenges, including declining revenues and persistent losses. However, positive technical indicators and promising corporate events provide some optimism. The valuation remains a concern due to negative earnings, but strategic developments in clinical trials and leadership could enhance future prospects.

To see Spark’s full report on AVTX stock, click here.

More about Avalo Therapeutics

Avalo Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation interleukin-1 beta (IL-1β) inhibitor therapies for immune-mediated inflammatory diseases. Its lead product candidate, AVTX-009, is an anti-IL-1β monoclonal antibody being advanced primarily for hidradenitis suppurativa (HS), a chronic inflammatory skin disease with significant unmet medical need, with potential application in additional inflammatory indications. The company highlights a seasoned management team with extensive pharma and biotech experience and reports an expected cash runway into 2028, positioning it to progress its pipeline through key clinical milestones in a HS market projected to exceed $10 billion by 2035.

Average Trading Volume: 353,666

Technical Sentiment Signal: Sell

Current Market Cap: $313.8M

For an in-depth examination of AVTX stock, go to TipRanks’ Overview page.